News - Bristol-Myers Squibb, Cardio-vascular

Filter

Popular Filters

1 to 25 of 54 results

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

EMA advisory committee backs addition for Eliquis SmPC

EMA advisory committee backs addition for Eliquis SmPC

02-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalRegulation

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

02-05-2014

Having achieved the biggest drug launch to date by generating an astonishing $2.3 billion in its first…

AbbVieAnti-viralsBayerBristol-Myers SquibbCardio-vascularDiabetesGilead SciencesHumiraJanuviaLantusMarkets & MarketingMerck & ConivolumabPharmaceuticalSanofiSovaldiXarelto

FDA approves new use for Bristol-Myers/Pfizer’ Eliquis

FDA approves new use for Bristol-Myers/Pfizer’ Eliquis

16-03-2014

The US Food and Drug Administration has approved pharma major Bristol-Myers Squibb’s supplemental New…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulationUSA

Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth

20-12-2013

The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

“Breakthrough Therapy” status for Portola’s andexanet alfa

25-11-2013

USA-based Portola Pharmaceuticals has been granted “Breakthrough Therapy” designation by the US Food…

andexanet alfaBayerBristol-Myers SquibbCardio-vascularEliquisNorth AmericaPharmaceuticalPortola PharmaceuticalsRegulationResearchXarelto

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

19-11-2013

Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPharmaceuticalPradaxaResearchXarelto

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

FDA should warn against prolonged use of Plavix for stent patients, says US consumer group

21-08-2013

The US Food and Drug Administration should warn patients and doctors that taking the widely prescribed…

Bristol-Myers SquibbCardio-vascularNorth AmericaPharmaceuticalPlavixRegulationSanofi

US FDA accepts Bristol-Myers/Pfizer' Eliquis sNDA

12-07-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and behemoth Pfizer (NYSE: PFE) announced that the US…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulation

Positive results from sub-analysis of Eliquis ARISTOTLE trial

07-05-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) and partner Pfizer (NYSE: PFE) reported results from a…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon

23-04-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis

05-04-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

Xarelto and Eliquis set to displace current therapies in DVT/PE

28-03-2013

Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis

23-01-2013

In final guidance published (January 23, 2013), UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbCardio-vascularEliquisEuropeJavlorOncologyPfizerPharmaceuticalPierre FabrePricingRegulation

Brazil's atrial fibrillation market expected to grow at 31% pa over next five years

22-01-2013

The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016,…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularDaiichi SankyoEliquisLixianaMarkets & MarketingPharmaceuticalPradaxaSouth AmericaXarelto

US FDA finally approves Bristol-Myers/Pfizer's Eliquis for stroke prevention in AF patients

31-12-2012

The US Food and Drug Administration on December 28 finally approved the anti-clotting drug Eliquis (apixaban),…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Brazil's atrial fibrillation market to grow at 31% annually over the next five years

19-12-2012

The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016,…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularDaiichi SankyoEliquisLixianaMarkets & MarketingPfizerPharmaceuticalPradaxaPricingSouth AmericaXarelto

1 to 25 of 54 results

Back to top